Ask any hospital procurement officer a few years ago where their MRI machine or ventilator came from, and the answer was almost always “imported.” That’s been changing faster than most people outside the industry realise — India’s medical devices market, valued at roughly $12-15 billion in 2026, is growing at 11-14 percent annually, and the government’s Production Linked Incentive scheme has already pushed 22 greenfield projects into commercial production, manufacturing everything from CT scanners to dialysis machines domestically for the first time. India’s medtech sector now ranks fourth in Asia behind Japan, China, and South Korea, and among the top 20 globally. Here are ten companies actually building the equipment inside that shift.
1. BPL Medical Technologies
BPL has been India’s homegrown answer to imported critical care equipment for decades, building a reputation specifically around cardiac and critical care technology at a time when most Indian hospitals defaulted automatically to foreign brands. Its complete healthcare solution approach spans diagnostic and monitoring equipment rather than a single narrow product category.
That established domestic manufacturing base gives BPL a genuine cost advantage over multinational competitors in India’s price-sensitive hospital procurement market, particularly for Tier 2 and Tier 3 city hospitals working with tighter capital budgets than metro flagship institutions.
2. Trivitron Healthcare
Trivitron has positioned itself as one of the fastest-growing medical equipment manufacturers in the country, spanning imaging systems, laboratory diagnostics, and critical care equipment, with a genuine export footprint reaching over 100 countries. That breadth across multiple device categories rather than a single specialty sets it apart from more narrowly focused competitors.
Its growth trajectory reflects a broader pattern among ambitious Indian medtech companies — building initial credibility in the domestic hospital market before pushing aggressively into export markets where Indian manufacturing cost advantages can undercut established Western and Japanese competitors on price without sacrificing regulatory compliance.
3. Meril Life Sciences
Meril has emerged as India’s most globally recognised medtech brand, building particular strength in cardiac stents and orthopaedic implants — categories requiring exceptionally rigorous clinical validation and regulatory approval before any hospital will use them on patients. That’s a genuinely harder bar to clear than diagnostic equipment, making Meril’s global recognition especially meaningful.
Cardiac stents and implants also carry considerably higher margins than commodity diagnostic devices, positioning Meril in one of the more profitable and technically demanding corners of India’s medical device industry, competing directly against established multinational implant makers on clinical outcomes rather than just price.
4. Skanray Technologies
Skanray, based in Mysuru, has built its identity around a specific and important mission — developing affordable, genuinely India-made imaging and ICU equipment rather than assembling imported components under an Indian brand name. That distinction matters enormously for India’s broader push toward medical device self-reliance.
By focusing on affordability without cutting corners on essential functionality, Skanray has positioned itself as a natural fit for India’s public healthcare expansion, where government hospitals and rural health infrastructure need genuinely capable equipment at price points that imported alternatives simply can’t match.
5. Poly Medicure
Poly Medicure has built a substantial global business in medical consumables — infusion therapy products, central venous catheters, and blood management systems — serving over 100 countries and backed by more than 215 product and process patents, a genuinely unusual depth of intellectual property for an Indian medical device company.
That patent portfolio reflects real investment in proprietary innovation rather than simply manufacturing established designs at lower cost, giving Poly Medicure a defensible competitive position in consumables categories where quality and reliability differences directly affect patient safety.
6. Transasia Bio-Medicals
Transasia holds a specific distinction as India’s largest in-vitro diagnostics company, with 42 years of experience building manufacturing centres, R&D operations, and international presence in the blood-testing world spanning hospitals, pathology labs, blood banks, and research institutes globally. Its product range covers biochemistry analyzers, immunoassay systems, and haematology equipment.
That deep specialisation in laboratory diagnostics rather than broader hospital equipment has let Transasia build genuinely global credibility in one specific, high-volume category, becoming a trusted name in blood-testing infrastructure across both public and private healthcare systems worldwide.
7. Wipro GE Healthcare
Wipro GE represents one of India’s longest-running medical technology joint ventures, established in 1990 between Wipro and GE, delivering advanced imaging, patient monitoring, and ultrasound solutions built on GE’s global engineering base combined with Indian manufacturing scale and cost structure.
That joint-venture model has proven durable precisely because it combines genuine technological depth from a global medical technology leader with the cost advantages and market knowledge that only a well-established Indian partner could provide, a formula several other multinational-domestic partnerships have since tried to replicate.
8. Siemens Healthineers India
Siemens Healthcare has operated in India since 1984, manufacturing advanced imaging technologies spanning X-ray, CT, and MRI systems alongside laboratory diagnostics and cancer care solutions. Globally, Siemens Healthineers holds roughly 23 percent of the diagnostic imaging market, a dominance that extends meaningfully into its Indian manufacturing and sales operations.
Its four-decade presence in India has let Siemens build deep relationships with major hospital chains and government procurement programmes, giving it an installed base and service network that newer entrants, domestic or multinational, would need years to replicate.
9. Allengers Medical Systems
Allengers has built a genuinely comprehensive imaging equipment business domestically, manufacturing X-ray, CT, and cath lab systems within India rather than importing finished units, directly targeting the segment of hospital imaging equipment historically dominated almost entirely by multinational brands.
That domestic manufacturing focus in a category traditionally seen as technically out of reach for Indian companies has made Allengers a genuine proof point for the PLI scheme’s broader ambition — showing that sophisticated imaging technology can be built competitively within India rather than only assembled from imported components.
10. AgVa Healthcare
AgVa built its reputation around low-cost ventilator technology, a category that became suddenly, urgently relevant during the COVID-19 pandemic when India faced acute shortages of imported ventilators and needed domestic production capability at genuine speed and scale.
That pandemic-era experience proved something important about Indian medtech capability under pressure — AgVa’s ability to rapidly scale affordable, functional ventilator production when international supply chains seized up demonstrated exactly the kind of manufacturing resilience the government’s broader medical device self-reliance push is now trying to institutionalise across the entire sector.
Frequently Asked Questions
Q1. Which companies are considered the largest Indian-origin medical device manufacturers, as opposed to multinational subsidiaries?
A: Trivitron, Meril Life Sciences, and BPL Medical Technologies are generally recognised as the largest Indian-origin medical device manufacturers, while multinational companies including GE HealthCare, Siemens Healthineers, Philips, Medtronic, and Abbott collectively hold roughly 40-45 percent of India’s overall medical devices market. Both categories manufacture significant volumes domestically, but the Indian-origin companies are typically the ones driving India’s export growth and self-reliance push specifically.
Q2. What is the Production Linked Incentive scheme for medical devices, and how has it affected domestic manufacturing?
A: The PLI scheme earmarked roughly ₹3,420 crore for 55 high-end medical device categories, offering a 5 percent incentive on incremental sales for four years to qualifying manufacturers, specifically to reduce India’s historical dependence on imported medical equipment. By September 2025, 22 greenfield projects had begun commercial production under the scheme, including equipment like CT scanners, dialysis machines, mammography systems, and MRI machines that were previously almost entirely imported.
Q3. How large is India’s medical device export market, and where is most growth expected?
A: India’s medical technology industry is projected to reach exports of up to ₹1,69,000 crore ($20 billion) by FY30 according to the Confederation of Indian Industry, with the January 2026 India-EU Free Trade Agreement specifically unlocking access to the EU’s $572.3 billion combined pharma and medtech market. India is also targeting a tripling of medical device exports to the UK specifically, from roughly ₹1,117 crore in 2024 to ₹2,917-3,493 crore by 2030.
Q4. What regulatory framework governs medical device manufacturing and approval in India?
A: The Medical Device Rules of 2017 govern the approval and manufacturing processes for medical devices in India, requiring adherence to safety and efficacy standards through the CDSCO regulatory body, alongside quality certifications like ISO 13485 for internationally exported products. Manufacturers targeting export markets typically need additional certifications specific to their destination, such as CE marking for Europe or FDA compliance for the United States, on top of domestic CDSCO approval.
Q5. Which categories of medical devices does India manufacture most successfully compared to categories that remain import-dependent?
A: India has built genuine manufacturing strength in cardiac stents, orthopaedic implants, IV cannulas, syringes, diagnostic reagents, and increasingly imaging equipment like X-ray and CT systems through companies like Meril, Poly Medicure, and Allengers. More technically complex, cutting-edge categories, particularly advanced robotic surgery systems and certain high-end MRI configurations, still lean more heavily on multinational manufacturers like Siemens Healthineers and GE HealthCare, though domestic capability in these areas continues expanding under PLI-driven investment.